Medifast, Inc.
11
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
9.1%
1 terminated/withdrawn out of 11 trials
90.9%
+4.4% vs industry average
0%
0 trials in Phase 3/4
30%
3 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Valued EpiGenetic Glycemic ImprovEments Through Weight Loss
Role: collaborator
Retrospective Chart Review of the 5 & 2 & 2 and 4 & 2 & 1 Plans
Role: lead
Weight Loss Using the Take Shape For Life Program or the Medifast Direct Program Versus a Self-Directed Diet
Role: lead
Arthritis Pilot for Preserving Muscle While Losing Weight
Role: collaborator
SUCCESS Tracking Study
Role: lead
Medifast 5 & 1 Plan
Role: collaborator
A Retrospective Chart Review of Three Medifast Weight Control Centers
Role: lead
Evaluation of Metabolism-Boosting Beverages
Role: lead
Comparison of Medifast's 5 & 1 Plan to a Food-based Plan of Equal Calories
Role: lead
Efficacy of 2 Diet Plans Designed for People With Type II Diabetes on Weight and Health Measures
Role: collaborator
Efficacy of Parent-Child Dieting Plans Incorporating Medifast Meal Replacements for Weight Loss
Role: collaborator
All 11 trials loaded